Agios Pharmaceuticals, Inc.

LSE:0HB0 Stock Report

Market Cap: US$1.5b

Agios Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Agios Pharmaceuticals has been growing earnings at an average annual rate of 39.9%, while the Biotechs industry saw earnings growing at 15.9% annually. Revenues have been growing at an average rate of 42% per year.

Key information

39.89%

Earnings growth rate

37.90%

EPS growth rate

Biotechs Industry Growth11.51%
Revenue growth rate41.99%
Return on equity-31.24%
Net Margin-895.86%
Next Earnings Update12 Feb 2026

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Agios Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

LSE:0HB0 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2545-4011800
30 Jun 25416501780
31 Mar 25376661670
31 Dec 24366741570
30 Sep 24336741400
30 Jun 2431-3651280
31 Mar 2429-3531230
31 Dec 2327-3521200
30 Sep 2324-2201170
30 Jun 2320-2101210
31 Mar 2319-2181190
31 Dec 2214-2321220
30 Sep 2210-3671200
30 Jun 226-3691180
31 Mar 221-3601190
31 Dec 210-3571210
30 Sep 210-342116221
30 Jun 210-337117221
31 Mar 210-336117221
31 Dec 200-3291150
30 Sep 2035-3471240
30 Jun 2061-3741290
31 Mar 2088-4021320
31 Dec 190-301102214
30 Sep 19112-4011290
30 Jun 19102-3891270
31 Mar 19116-3481210
31 Dec 1894-3461140
30 Sep 1874-3431050
30 Jun 1870-325910
31 Mar 1841-339810
31 Dec 1743-315710
30 Sep 1756-283640
30 Jun 1753-269580
31 Mar 1749-241550
31 Dec 1670-198510
30 Sep 1653-183460
30 Jun 1650-160440
31 Mar 1656-136400
31 Dec 1559-118360
30 Sep 1568-104320
30 Jun 1596-60280
31 Mar 1591-46230

Quality Earnings: 0HB0 is currently unprofitable.

Growing Profit Margin: 0HB0 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 0HB0 is unprofitable, but has reduced losses over the past 5 years at a rate of 39.9% per year.

Accelerating Growth: Unable to compare 0HB0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0HB0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (118.6%).

Return on Equity

High ROE: 0HB0 has a negative Return on Equity (-31.24%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/06 08:33
End of Day Share Price 2026/02/06 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Agios Pharmaceuticals, Inc. is covered by 31 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
George FarmerBMO Capital Markets Equity Research
Alec StranahanBofA Global Research